INTRODUCTION BCR-ABL is formed by the reciprocal translocation of breakpoint cluster region (bcr) sequences on chromosome 22 with the c-abl gene on chromosome 9. 1 The t(9;22) translocation is harbored by the majority of patients with chronic myeloid leukemia (CML) and a small percentage of pediatric patients with acute lymphoblastic leukemia. BCR-ABL translocation variants encode proteins of 190, 210, and 230 kDa in size; however, CML is most prominently associated with the p210 isoform. 2 CML is characterized by a massive expansion of myeloid cells and their premature release from the bone marrow into the peripheral blood. The deregulated proliferation of these leukemic cells is owing to the ability of BCR-ABL to confer factorindependent growth and protection from apoptosis, [3] [4] [5] [6] [7] while retention of cells within the bone marrow is dependent on the interplay between adhesive and migratory forces. CML cells show inefficient adhesion to bone marrow stroma and the extracellular matrix component fibronectin. 8, 9 As well, CD34 þ CML cells display enhanced spontaneous motility. 10, 11 These alterations in cellular proliferation, apoptosis, adhesion and migration contribute to CML pathogenesis.
BCR-ABL-mediated pathogenesis of chronic phase CML is accurately reproduced in the murine bone marrow transplantation (BMT) model. BCR-ABL-transduced bone marrow progenitors are intravenously injected into lethally irradiated recipient animals in this assay. These cells home to the bone marrow niche where they reconstitute the hematopoietic compartment. The BCR-ABLexpressing cells display a growth advantage, and within B 3 weeks, the BMT recipients succumb to a fatal myeloproliferative disease (MPD) that resembles human CML. 12, 13 The oncogenic capacity of BCR-ABL results from deregulated tyrosine kinase activity 14 and enhanced activity relative to c-Abl.
14,15 BCR-ABL constitutively activates several cell signaling cascades, including the RAS/ERK, 16 PI3'K, 17 STAT, [18] [19] [20] [21] JNK,  22 p38   23 and RAC pathways. 24 Of these, the GRB2 and SHC, 16, 25 PI3'K, [26] [27] [28] CrkL, 29 Crk and CBL proteins 26, 30, 31 are key downstream signaling intermediates.
CBL is prominently tyrosine phosphorylated by BCR-ABL. 32 The v-Cbl retrovirus was the original CBL family member identified, which caused B-cell lymphomas and myeloid leukemias in mice. 33 The family consists of three mammalian members-Cbl, Cbl-b and Cbl-3. Single gene deletions of the Cbl family members demonstrates that these genes are not essential for murine development, [34] [35] [36] [37] however, the Cbl-and Cbl-b-deficient mice exhibit defects in T cell development and activation, respectively.
Cbl proteins act as adapter molecules and E3 ubiquitin ligases. 38 Cbl family members also control hematopoietic cell motility; for example, both CBL and CBL-B positively regulate SDF-1a-stimulated motility of Jurkat T cells. 39, 40 As SDF-1a is a major chemokine known to regulate homing of cells to the bone marrow, CBL proteins may critically regulate this key step in BMTs.
CBL expression is required for efficient BCR-ABL-dependent in vitro cell transformation, 41 but dispensable for leukemogenesis in the BMT model. These results suggest that other proteins can compensate in vivo for the loss of CBL. As Cbl-b shows significant hematopoietic tissue expression, 42 this CBL family member could has an essential role downstream of BCR-ABL. Interestingly, Cbl-b protein levels are reduced by BCR-ABL expression, and the introduction of Cbl-b into BCR-ABL-expressing Ba/F3 cells augments spontaneous motility.
In this study, we used the murine BMT assay to assess the role of Cbl-b in the development of BCR-ABL-induced leukemia. Recipients of Cbl-b( À / À ) BCR-ABL BMCs succumbed to a longer latency MPD, with a reduced leukemic burden at morbidity but enhanced granulopoiesis, when compared with the wild-type BCR-ABL transplant animals. The shortened latencies in intrafemoral transplants suggest that Cbl-b-dependent regulation of motility accounts for the prolonged survival of animals receiving Cbl-b-deficient BCR-ABL-expressing leukemic cells through canonical BMTs.
MATERIALS AND METHODS

DNA constructs
pcDNA3-TEL-JAK2 5-19 was described previously. 44 pGD-210 (BCR-ABL) was provided by R. van Etten (Boston, MA, USA). The Mig210 construct provided by M. Carroll (Philadelphia, PA, USA) was used to express the p210 isoform of BCR-ABL in bone marrow cells and was previously demonstrated to efficiently generate MPD in mice. 45 The vesicular stomatitis virus G-expression plasmid was supplied by G Sauvageau (Montreal, QC, Canada). MSCV-IRES-EGFP (MIEV) and the Gag/Pol vector (SV-c --env -) were provided by JE Dick (Toronto, ON, Canada).
Cell culture
Ba/F3 cells expressing pcDNA3, pcDNA3-TEL-JAK2 [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] or pGD-210 (BCR-ABL) were generated and cultured as previously described. 46 The 293 T cells were expanded in Iscove's modified Dulbecco's media plus antibiotics supplemented with 10% fetal calf serum (FCS).
Animals
Studies were approved by the Animal Care Committee at the Ontario Cancer Institute, University Health Network, Toronto, ON, Canada. Cbl-bheterozygous matings in the BALB/c line produced both wild-type (Cblb( þ / þ )) and Cbl-b( À / À ) donor animals. BALB/c recipient mice were obtained from Jackson Laboratory (Bar Harbor, ME, USA). Mouse genotypes were determined through PCR amplification as described previously. Bone marrow transduction and transplantation Donor and recipient mice were used at 6-8 weeks of age. Donor mice were primed with intraperitoneal injection of 200 mg per kg of 5-fluorouracil (Sigma-Aldrich, St. Louis, MO, USA) 4 days before bone marrow harvest. 47 Bone marrow cells were flushed from femurs and tibias with prestimulation cocktail of high glucose (H21) Dulbecco's modified Eagle's medium plus antibiotics, 10% FCS, 5% WEHI IL (interleukin)-3-conditioned media, 6 ng/ml recombinant murine IL-3 (rmIL-3), 10 ng/ml rmIL-6 and 50 ng/ml recombinant murine stem cell factor. All cytokines were purchased from R&D Systems Inc. (Minneapolis, MN, USA). Cells were plated, without lysis of erythrocytes, into adherent-cell culture dishes at a concentration of 1 Â 10 6 white blood cells (WBCs)/ml in prestimulation cocktail. Twenty-four hours post-plating, trypsinized bone marrow cells at a concentration of 1 Â 10 6 WBCs/ml, were subjected to two 24 h rounds of infection in prestimulation cocktail containing 3 mg/ml Polybrene and virus at a final infectious dose of 2 Â 10 5 CFUs/ml. Transduced bone marrow cells were collected, washed and resuspended to 1.2 Â 10 6 WBCs/ml in phosphate-buffered saline. Following lethal irradiation, (9 Gy) each mouse received 5 Â 10 5 WBCs through intravenous injection. For intrafemoral transplantation, transduced bone marrow cells were resuspended before injection in phosphate-buffered saline at a concentration of 1.67 Â 10 7 WBCs/ml. Injections were performed as described previously, 48 with 5 Â 10 5 cells in a volume of 30 ml injected with a 0.5-ml insulin syringe and 28G needle.
Analysis of diseased mice
Recipient mice were monitored regularly for signs of disease. Periodic peripheral blood WBC counts were obtained from saphenous vein bleeds. Premoribund animals were killed and hematopoietic tissues were harvested. Peripheral blood smears and bone marrow cytospins were stained with May-Grü nwald and Giemsa (EMD Chemicals Inc., Gibbstown, NJ, USA), while the spleen, liver and lung sections were stained with hematoxylin and eosin (Sigma-Aldrich). Spleen and liver single-cell suspensions were created by manual force through wire mesh and erythrocytes were lysed with ACK (pH 7.3; 155 mM ammonium chloride, 100 mM disodium EDTA and 10 mM potassium bicarbonate).
CBL-B(+/+) BCR-ABL (n=7)
CBL
Antibodies
All flow cytometry antibodies were acquired from BD Biosciences including: phycoerythrin (PE)-conjugated anti-mouse Thy-1.2 (53-2.1), CD4 (H129.19), TER-119, B220 (RA3-6B2), Sca-1 (D7) and Gr-1 (RB6-8C5); PerCP-Cy5.5-conjugated rat monoclonal CD8a (53-6.7) and CD11b/Mac-1 (M1/70); and allophycocyanin (APC)-conjugated CD117/c-Kit (2B8).
Flow cytometry
All the cells were blocked with antimouse CD16/CD32 (2.4G2; BD Biosciences) and stained with a combination of antibodies as described above. Measurements were made on a FACSCalibur machine (BD Biosciences) and data were analyzed with FlowJo software (Ashland, OR, USA).
Homing assay
Bone marrow cells were ACK-treated and labeled with PKH26 dye (SigmaAldrich) according to the manufacturer's instructions. Labeled cells (5 Â 10 6 ) were intravenously injected into lethally irradiated BALB/c recipients. Control animals were injected with phosphate-buffered saline alone. Three hours after transplantation, bone marrow and spleen cells were retrieved and erythrocytes lysed with ACK. Cells were washed once with phosphate-buffered saline and the percentage of fluorescent cells in each tissue was measured by flow cytometry.
RESULTS
Cbl-b deficiency lengthens the latency of leukemogenesis BMT experiments were conducted to determine the role of Cbl-b in BCR-ABL-induced leukemia. Within 3 weeks of transplantation, all the mice receiving wild-type BCR-ABL-transduced bone marrow cells succumbed to a fatal MPD that closely resembled human CML (Figure 1 ). These mice displayed elevated WBC counts (18-242 Â 10 6 /ml) with a differential shift toward mature neutrophils (Figures 1b and d) . Enhanced numbers of nucleated erythroid cells were also observed. The bone marrow was hypercellular due to the expansion of maturing granulocytes and fully differentiated neutrophils (Figure 2a) . Extramedullary hematopoiesis was evidenced by splenomegaly (0.2-0.9 g) and hepatomegaly (1.5-3 g) ( Table 1 ; Figure 1c) , with myeloid cells infiltrating both of these organs (Figure 2b) . A high number of immature nucleated erythroid cells were also observed in the spleens. These recipients showed signs of pulmonary hemorrhage (Figure 2b) , the probable cause of death.
Although 100% of the wild-type BCR-ABL-infected recipients died within 21 days of transplantation, the Cbl-b( À / À ) BCR-ABL recipients exhibited a prolonged latency of disease development (Figure 1a ; median ¼ 27 days, mean ¼ 28 days; P ¼ 0.0106 as determined by the log-rank test). These animals displayed an MPD with bone marrow myeloproliferation, extramedullary hematopoiesis and pulmonary hemorrhaging to a similar extent as the wild-type counterparts (Figure 2 ). Yet, the Cbl-b( À / À ) recipients showed tighter distributions of peripheral blood counts (43-127 Â 10 6 cells/ml; P ¼ 0.1416, Mann-Whitney test) and spleen weights (0.3-0.5 g; P ¼ 0.0735, Mann-Whitney test) and a trend toward decreased cellularity as compared with the wild-type MPD animals (Figures 1b and c) . The differential counts of the Cbl-b ( À / À ) BMT animals displayed a larger expansion of granulocytes (compared with the wild-type mice) that overwhelmed the lymphocyte population (Figure 2d ). (Figure 3a) . In contrast, the vector control-infected mice showed minimal splenic infiltration of GFP þ cells. The percentages of Gr-1 þ /Mac-1 þ granulocytes and TER-119 þ erythroid cells were considerably increased in the diseased animals. The Gr-1 þ and Mac-1 þ GFP-negative (GFP -) cells were also amplified, possibly through enhanced cytokine production from BCR-ABL þ cells. 49 As well, Gr-1 displayed a wide range of expression, indicative of the expansion of both mature and immature myeloid cells in the spleen. This contrasts with peripheral blood Gr-1 expression where most cells had very high levels of Gr-1 and were therefore, more differentiated (data not shown). The percentages of amplified splenic myeloid cells varied between the genotypes: Cbl-b-deficient recipients showed enhanced Gr-1 þ and Mac-1 þ percentages compared with their wild-type counterparts, with a statistically significantly increase in Mac-1 þ cells (Figure 3b ; t-test, P ¼ 0.05). These data are akin to the observations in the peripheral blood, where Cbl-b deficiency enhanced granulopoiesis.
Cbl-b knockout cells display decreased homing to the bone marrow Okabe et al. 39 showed that Jurkat T cells treated with CBL-Bspecific small inteference RNA were less motile toward SDF-1a than untreated cells. As SDF-1a is the major chemokine controlling bone marrow cell homing, we hypothesized that Cbl-b( À / À ) intravenously injected cells may be impaired in their homing to the bone marrow microenvironment, and that the resulting reduction in cell numbers may account for the delayed latency and reduced leukemic burden. To test this hypothesis, we performed in vivo homing assays with the use of fluorescent cell markers. Bone marrow cells were isolated from wild-type and Cbl-b( À / À ) animals and labeled ex vivo with PKH26. Equivalent labeling of wild-type and Cbl-b( À / À ) cells was apparent (Figure 4 ). Labeled cells were intravenously transplanted into irradiated recipients and allowed to migrate for 3 h. Mice were then killed and cell suspensions were created from the bone marrow and spleen. The percentages of homed PKH26-stained cells were determined by flow cytometry (Figure 4 ). There was a statistically significant decrease in the ability of Cbl-b( À / À ) cells to home to the bone marrow (Figure 4 ), while splenic homing was similar between recipients of wild-type and Cbl-b knockout cells (Figure 4 ). These figures point to a positive role for Cbl-b in regulating homing to the bone marrow.
50
Long latency of Cbl-b( À / À ) BCR-ABL disease is collapsed by intrafemoral introduction of bone marrow cells We hypothesized that the homing defect of Cbl-b( À / À ) cells might be responsible for the extended latency of leukemogenesis in the Cbl-b( À / À ) BCR-ABL transplants and that direct intrafemoral injection may result in a reduced time to disease development.
Wild-type and Cbl-b-deficient cells were transduced with BCR-ABL (as described above) and injected directly through the knee cap into the femur bone of recipient animals. All transplanted mice succumbed to a CML-like MPD 3-4 weeks postinjection. There was no disparity in disease latency between the wild-type and Cbl-b knockout mice (Figure 5a ; log-rank test P ¼ 0.37), nor DISCUSSION CBL and CBL-B are highly phosphorylated in BCR-ABL-expressing cell lines 32, 43, 51 and CBL is a phosphorylated target in chronic phase CML cells. 30 Yet in vivo, Cbl is dispensable for CML disease development. 41 Given that BCR-ABL expression downregulates Cbl-b, it is conceivable that this protein is the primary CBL family member involved in CML. Cbl-b( À / À ) BCR-ABL-infected bone marrow cells are less effective at inducing leukemia in mice as compared with animals receiving wild-type BCR-ABL-transduced cells. The Cbl-b( À / À ) BCR-ABL recipients have delayed disease latency that is not due to ineffective generation of granulocytes, but rather an impaired ability of the Cbl-b( À / À ) cells to home to the bone marrow niche.
BCR-ABL significantly altered CBL-B protein levels in vitro, so we initiated BMTs to assess the contribution of Cbl-b in BCR-ABLmediated MPD development. The wild-type BCR-ABL recipients became moribund B 3 weeks post-transplant and succumbed to an MPD. An MPD was also observed in the majority of the Cbl-b( À / À ) BMTs, but with key phenotypic differences from the wild-type recipients.
The Cbl-b( À / À ) MPD was distinct in multiple respects. Compared with the wild-type MPD animals, the Cbl-b( À / À ) recipients displayed (i) enhanced granulopoiesis in the peripheral blood and spleen, (ii) reduced leukemic burden at the time of morbidity and (iii) prolonged survival. The first observed difference was the more effective granulocyte production in the Cbl-b ( À / À ) BCR-ABL BMTs. Differential counts showed enhanced numbers of neutrophils with a consequential decrease in the percentage of lymphoid cells. Additionally, flow cytometric spleen cell analyses showed elevated percentages of both GFP þ and GFP -granulocytes. The Cbl-b( À / À ) intrafemoral transplant recipients also showed a trend toward enhanced leukocyte numbers in the peripheral blood and spleen, although these data were not statistically significant. These findings suggest that Cbl-b may function as a negative regulator of myeloid proliferation.
Several groups initially argued that BCR-ABL controlled granulopoiesis through autocrine production of IL-3, granulocytecolony-stimulating factor and granulocyte macrophage-colonystimulating factor. 49, 52 Yet, BCR-ABL BMTs later showed that MPD development was unaltered by the deletion of IL-3 or granulocyte macrophage-colony-stimulating factor cytokines and IL-3 receptor chains, 53, 54 suggesting that BCR-ABL must control granulopoiesis through an alternative mechanism. On the basis of our findings in Cbl-b( À / À ) recipients, we propose that BCR-ABL may actively reduce CBL-B expression to promote myeloid expansion. In support of our hypothesis, several recent studies suggest that CBL mutations cooperate in the pathogenesis of myeloid malignancies. Mono-or bi-allelic mutations of CBL proteins in regions that coordinate ubiquitination have been found in patients with acute myeloid leukemia, 55, 56 myelodysplastic syndrome/MPD, and chronic myelomonocytic leukemia. 57 Moreover, mice with Cbl RING-finger domain knockin mutants develop MPDs that progress to leukemia, 58 and mice with combined deficiency of Cbl and Cbl-b in the hematopoietic stem cell compartment succumb to MPD. 59 The second phenotypic difference in the Cbl-b( À / À ) MPD animals was the presence of morbidity in the absence of significant leukemic burden (that is, high peripheral blood WBC counts and massive splenic extramedullary hematopoiesis). Several groups suggest that the ultimate cause of death in murine CML transplants is not the level of leukemic burden, but rather the infiltration of mature myeloid cells into the lungs and the consequential lung hemorrhage. 47, 50 Moreover, BMTs performed with the mutant Y177F BCR-ABL yield T-cell lymphomas, and the absence of pulmonary involvement [60] [61] [62] suggest that a mere transformation of leukemic phenotype away from a myeloid disease spares the animals from lung manifestation. Therefore, we argue that the prominent neutrophil expansion in the Cbl-b( À / À ) MPD animals led to infiltration of the lungs sufficient for morbidity in the absence of massive leukemic burden. This conclusion is supported by pulmonary sections from the Cbl-b( À / À ) MPD mice that show comparable hemorrhaging to wild-type recipients (Figure 2b) .
The third, and the most striking difference in our Cbl-b( À / À ) BCR-ABL animals, was the delayed latency of disease development. Analysis of protein expression did not identify a plausible mechanism to explain this difference (data not shown). Phosphotyrosine profiles of the diseased animals were identical and the levels of BCR-ABL expression were similar (data not shown). Furthermore, the intensity of Pkb and Erk1/2 phosphorylation was reflective of the number of infiltrating leukemic cells in the splenic compartment and was not distinctly regulated by Cbl-b (data not shown). Therefore, we speculated that cell survival and proliferation, respectively, were not appreciably different and could not account for the delayed latency. Our preliminary colony formation assays did not show any significant difference in the ability of Cbl-b( À / À ) cells to form myeloid colonies (data not shown). The growth rate of BCR-ABL-expressing Ba/F3 cells is not altered by forced expression of CBL-B. 43 Therefore, we predicted that Cbl-b perturbed leukemogenesis through the modulation of cellular migration to the bone marrow. Our initial short-term homing assays suggested a modest decrease in the homing capability of Cbl-b-deficient cells to the bone marrow niche (Figure 4) . Nevertheless, the intrafemoral transplants yielded Cbl-b( À / À ) and wild-type BCR-ABL diseases with identical latency and pathology. We conclude that decreased homing of the Cbl-b-deficient cells to the bone marrow-the major site of hematopoiesis-impairs proliferation of the CML progenitors, which consequently retards leukemic progression. Skorski et al. 63 showed that 32D cell lines transduced with SH3 deletion mutants (DSH3) of BCR-ABL had impaired homing leading to decreased tissue infiltration as a function of time and prolonged survival compared with the recipients of wild-type BCR-ABL cells. This DSH3-BCR-ABL protein abnormally localized to the cytosol. As CBL-B can co-immunoprecipitate BCR-ABL, 43 contains a proline-rich motif that could potentially interact with the BCR-ABL SH3 domain, and can alter cellular localization of the PI3'K p85 subunit, 64 we postulate that CBL-B may regulate BCR-ABL distribution. A link between the association of the BCR-ABL SH3 domain with CBL-B, cytoskeletal localization and efficient homing would be of great interest for further evaluation of transplant outcomes.
Furthermore, data suggest that signals other than SDF-1 a may regulate engraftment of BCR-ABL þ cells: CD44 expression of hematopoietic stem cell/Ps modulates cell homing, 65 while P-selectin has a role in bone marrow retention. 50 Cbl-b negatively regulates receptor signaling downstream of growth factor, cytokine, antigen and chemokine receptors. Cbl participates in inside-out signaling with b1-integrins whereas Cbl-b regulates b2-integrin signaling downstream of LFA-1. 66 CBL is one of the primary tyrosine phosphorylated substrates in chronic phase CML patient samples. 30 Cbl-b is also a target of the BCR-ABL kinase, as phosphorylation of Cbl-b is observed in imatinib-resistant BCR-ABL. 51 Antigen receptor activation results in recruitment of CrkL-C3G complex that leads to activation of Rap1. 67 Further research is required to determine whether these pathways are active and to identify the cellular ubiquitination targets of CBL and CBL-B in primary CML.
The observed Cbl-b-specific differences in BCR-ABL-mediated disease can be summarized in a single model. Cbl-b( À / À ) cells are less efficient at homing to the bone marrow then their wildtype counterparts. The wild-type cells proliferate rapidly, while the decreased number of Cbl-b( À / À ) cells in this organ gives the impression of slower proliferation, even though the growth rates of wild-type and Cbl-b( À / À ) bone marrow cells are comparable. Egress of wild-type cells proceeds at a faster rate than for the Cblb( À / À ) cells, leading to a hastened disease latency. This is observed in Gr-1 þ myeloid cells, which are elevated in Cbl-bdeficient transplant recipients, however, Cbl-b( À / À ) recipients possess a longer latency. Similarly, Cbl-b( À / À ) macrophages display increased adhesion to endothelial cells. 66 Nevertheless, the bone marrow niche in the Cbl-b( À / À ) BMTs continues to increase in cellularity until leukemic cells migrate into the peripheral blood and evade other organs, eventually causing death.
We conclude that Cbl-b functions in vivo as a negative regulator of BCR-ABL-mediated granulopoiesis. BCR-ABL may reduce Cbl-b expression levels to enhance granulocyte proliferation, a characteristic feature of CML. Additionally, our studies show an essential positive regulatory role for Cbl-b in bone marrow cell homing, revealed as attenuation of disease development in the traditional BCR-ABL transplant model. Experimental conditions that eliminate the homing component of BMTs are necessary for future investigations of Cbl-b deficiency in the context of BCR-ABL-mediated leukemogenesis.
